作者: Michael A. Bukys , Jan Jensen
DOI: 10.1007/978-1-60761-366-4_10
关键词: Clinical uses of mesenchymal stem cells 、 KOSR 、 Induced stem cells 、 Immunology 、 Cellular differentiation 、 Embryonic stem cell 、 Embryoid body 、 Stem cell 、 Cell biology 、 Progenitor cell 、 Biology
摘要: Beta-cell replacement is an effective treatment for type 1 diabetes, but its applicability limited by the lack of sufficient donor tissue, raising need alternative tissue sources. Deriving β cells from stem cell precursors offers unlimited renewable source transplantation and in recent years has become focus research many laboratories. The unique state embryonic (ES) characterized continuous proliferation through a cycle consisting abbreviated G1 phase. Although this exposes ES to potential mutations, it also allows culture undifferentiated cells. Current protocols directing differentiation mimic normal development definitive endoderm, foregut pancreatic precursors, endocrine progenitor At present all these steps are suboptimal, since only some follow pathway intended product. Moral concerns surrounding use led sources pluripotent advances cellular reprogramming discussed.